{"analyses":[{"ciLowerLimit":"0.69","ciNumSides":"TWO_SIDED","ciPctValue":"95.03","ciUpperLimit":"1.11","estimateComment":"Stratified Cox proportional hazard model","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.88","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median not reached due to insufficient death events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median not reached due to insufficient death events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"453"},{"groupId":"OG001","value":"453"}],"units":"Participants"}],"description":"OS is defined as as the time between the date of randomization and the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV q2 wks and Ipilimumab placebo IV q3 wks for 4 doses then q12 wks starting at Wk 24","id":"OG000","title":"Nivolumab 3 mg/kg"},{"description":"Ipilimumab 10 mg/kg IV q3 wks for 4 doses then q12 wks starting at Wk 24 and Nivolumab placebo IV q2 wks","id":"OG001","title":"Ipilimumab 10 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All randomized Participants","reportingStatus":"POSTED","timeFrame":"up to 106.6 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}